Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — RPG Annual Investor Conference 2024
14 slides from Rpg Life Sciences's conference presentation, Jun 6, 2024
Slide 1: Investor Presentation filing letter to stock exchanges
L RPO LIFE SCIENCES RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91 ·22-24981650 I 66606375 Fax:+91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com June 06, 2024 CIN: L.24232MH2007PLC169364 To The Manager BSE Limited
Slide 2: Annual Investor Conference 2024
•• hello happiness V Annual Investor Conference 2024 RPG Life Sciences June 7, 2024
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. APIs Domestic Formulations (DF) Develop, manufac
Slide 5: FY 2023-24 delivers A Strong All-Round Performance
FY 2023-24 delivers A Strong All-Round Performance ROCE ROE EPS 14% 26% + 229 bps 31.0% 23.4% Rs. 53.0 New Products Contribution** Growth Evolution Capitalization ~30% 13.0%* 110% +5 +118% 7th Fastest growing Company in the Top 75 Companies of IPM* * IQVIA TSA MAT Mar ‘24 ** Launched onwards FY19 ~»
Slide 6: Profit Margins: A Trajectory of y-o-y expansion continues un-interrupted
Profit Margins: A Trajectory of y-o-y expansion continues un-interrupted EBITDA% 23.3% 21.0% 20.3% 20.2% 18.2% 17.9% ` 16.6% 15.9% PAT% 13.8% 15.1% 11.1% 11.1% 13.2% 10.4% 9.8% 9.3% 8.7% 11.7% 8.1% 10.3% 6.0% 6.2% 5.9% 4.7% 7.7% 4.2% 4.6% 4.2% 3.9% 3.9% 0.9% 0.4% 0.4% 3.3% 0.5% 0.2% FY 12 FY 13 FY 1
Slide 7: Revenues, Profit, Cashflows: A strong y-o-y upward Trajectory
Revenues, Profit, Cashflows: A strong y-o-y upward Trajectory continues un -abated Rs Crores Revenue Up by 14% vs LY PBT up by 29% vs LY Good cashflow generation I fY 582.1 117.8 115.2 127.6 512.8 440.2 91.7 375.6 389.1 73.2 70.3 330.2 53.6 40.3 41.8 15.1 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21
Slide 8: Key Financial Ratios: A Trajectory of y-o-y uptrend continues
Key Financial Ratios: A Trajectory of y-o-y uptrend continues un-abated EPS ROCE % ROE % 31.0% 23.4% 22.0% 29.7% 28.5% 20.1% 53.0 18.5% 24.9% 16.4% 40.9 20.9% 31.1 24.2 17.5 9.7% 6.7% 6.5 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 ROCE = (PBT + Finance
Slide 9: Consistent Operating Performance reflecting in Market Cap leapfrogging
Consistent Operating Performance reflecting in Market Cap leapfrogging ,v9X... BSE Healthcare Index RPGLS Market Cap 35,052.8 2,527.9 12,148.6 280.8 31 Mar'20 31 Mar'24 31 Mar'20 28 Mar '24 L R?G UFE SCIENCES
Slide 10: Strategic Initiatives enabling Performance
Strategic Initiatives enabling Performance 1 Comprehensive Life Cycle Management of Legacy products Naprosyn crosses Rs. 73 Cr in FY24 - on its way to become first 100 crore Brand 2 New Product Launches across segments New Products contribute ~30% to Domestic Formulation Sales 3 Foray into New Thera
Slide 11: ESG Progress Update FY24
ESG Progress Update FY24 Environment Goals Social Goals Governance Goals Carbon Emission Diversity & Inclusion Data Integrity 27% reduction in FY24 Roadmap to reach 10% - Digitalization across Plants reached ~6% (FY24) Energy Efficiency Cybersecurity Tree Plantation [i] 26% reduction in FY24 IT asse
Slide 12: Summarizing – The Journey of RPG Life Sciences so far
Summarizing – The Journey of RPG Life Sciences so far ... 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixing Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidi
Slide 13: RPGLS Journey Ahead... Strategic Pillars of Action
RPGLS Journey Ahead... 7 Strategic Pillars of Action 1 2 3 4 5 6 7 State-of-art Targeted Institutionalized Focused Lead Therapy uilding PLANTS R&D PIPELINE enablement ADJACENT Spaces Talent Development EU/PICS/TGA/ Focused across 3 Institutionalization Technology Framework – RPGLS Identify and segme
Slide 14: hello happiness
•• V hello happiness
RPG Life Sciences — RPG Annual Investor Conference 2024 on 6ix